Targeted Therapy: 720 Real Stories

720 stories match targeted therapy. 488 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Stable Brain Metastases During Niraparib Maintenance for Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CA-125 4019 kU/L; pathogenic germline BRCA1 mutation

Metastatic Site: brain

After 17 months of niraparib, her brain metastases remained stable. She had a performance status of 0 and reported a full, normal quality of life.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Nocardia Infection Mimicked Breast Cancer Lung Metastases

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive.

The lung nodules resolved with antibiotics and proved infectious rather than metastatic; she remained in good health at the last follow-up in January 2019.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Cancer Relapse Causing Fluid Around the Heart

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: PAX8 positive; CK7 positive; WT1 positive; p53 positive; ER positive; PR negative; isolated PMS2 loss; MSH2 retained; MSH6 retained; MLH1 retained; two BRCA1 variants of uncertain significance

Metastatic Site: omentum|pericardium

She was alive after completing chemotherapy for the pericardial relapse and was receiving olaparib maintenance. The fluid around the heart did not recur immediately after the surgical window.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colorectal Cancer Treatment Complicated by Severe Lung Inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: KRAS wild type; NRAS wild type

Metastatic Site: liver

He recovered from the severe treatment-related lung inflammation, was weaned off oxygen within 1 month, and continued oncology follow-up while living with Stage IV colorectal cancer.

PubMed Central
OutcomeLiving With Cancer
Amanda, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ALK Lung Adenocarcinoma: Amanda's Survivor Story

Patient Info: Amanda Nerstad, Under 40 | Stage IV

Biomarkers: ALK-positive

She achieved a complete metabolic response on alectinib and had shown no evidence of disease since November 2017 while continuing treatment.

MD Anderson
OutcomeCancer-Free / NED
Jane, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Jane's Survivor Story

Patient Info: Jane Dennington, Female, 60s

Biomarkers: HER2-positive breast cancer

As of January 2019, Jane was cancer-free for almost 5 years after HER2-positive breast cancer treatment with chemotherapy, Herceptin, surgery and Kadcyla through the KATHERINE clinical trial.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

HER2-amplified metastatic colon cancer treated with afatinib after several therapies

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: RAS wild-type; BRAF wild-type; HER2 amplification; HER2 mutation

Metastatic Site: liver|abdominal wall|lung

After multiple treatment lines and a 3-month period of stable disease on afatinib, the cancer progressed again. He died in January 2018 from severe lung infection and kidney failure.

PubMed Central
OutcomeIn Memory
SI
Breast Cancer

Stage II HER2-Positive Breast Cancer With Anti-Yo Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: HER2 positive

Her severe anti-Yo paraneoplastic cerebellar syndrome did not meaningfully respond to IVIG or cancer treatment. She became wheelchair-dependent and ultimately required long-term care, with only moderate improvement in ataxia after rehabilitation.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Breast AdenocarcinomaBreast Cancer

Breast Cancer Recurring 18 Years After Mastectomy

Patient Info: Anonymized, Female, 70+ | Stage Metastatic/Advanced

Metastatic Site: sternum|lungs|pleura|chest wall

She died during respiratory decline caused by both metastatic breast cancer in the lungs and a separate primary lung cancer.

PubMed Central
OutcomeIn Memory
AO
Ovarian Cancer

Advanced Ovarian Cancer Presenting With Dermatomyositis

Patient Info: Anonymized, Female, 50s

Biomarkers: CA-125 3169 at diagnosis; later CA-125 rise with progression

After a partial response to second-line chemotherapy, nodal disease progressed again 5 months later and liposomal doxorubicin was planned.

PubMed Central
OutcomeSetback / Progression
OC
Ovarian Cancer

Ovarian Cancer With Pleural Spread and Recurrent Dermatomyositis

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Metastatic Site: pleura

She had symptomatic improvement after 2 cycles of carboplatin and liposomal doxorubicin for recurrent disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Rectal Cancer Spreading to the Thyroid and Bones

Patient Info: Anonymized, Male, 40s | Stage Metastatic/Advanced

Biomarkers: CEA 2.75 ng/mL at diagnosis

Metastatic Site: thyroid|bones

His metastatic disease worsened after 3 cycles of bevacizumab and capecitabine. He declined further treatment and died at home within 2 months.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence involving the bladder and bones

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial breast cancer: ER-positive, PR-positive, HER2-negative. Bladder metastasis: ER-positive, PR-negative, HER2 1+.

Metastatic Site: bladder, bone, rectosigmoid region, anorectal region

She died in October 2016 from pulmonary haemorrhage, 47 months after metastatic disease was diagnosed.

PubMed Central
OutcomeIn Memory
Molly, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Molly's Patient Story

Patient Info: Molly Golbon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Left hip; right shoulder; brain

Molly had a strong early response to Tarceva for Stage IV EGFR-mutated lung cancer, with about 50% tumor shrinkage after 2 months and metastatic disease described as almost undetectable; no later remission/NED status is provided in this record.

The Patient Story
OutcomeResponding Well